What is the Concord Drugs Ltd share price today?

The share price of BSE:CONCORD-X on 01 Oct 2026 (as of 15:05:40 IST) is ₹75.7.

What is the BSE:CONCORD-X 52 week high low price?

Over the past 52 weeks (as of 01 Oct 2026), the BSE:CONCORD-X 52 week high low range shows a high of ₹92.52 and a low of ₹61.

What is the Concord Drugs Ltd market cap?

As on 01 Oct 2026, Concord Drugs Ltd market cap is ₹981933000.

What is the shareholding pattern of Concord Drugs Ltd Stock?

The shareholding pattern of Concord Drugs Ltd, as of last reported-on 30 Jun 2026 is: Promoters: 45.08% Foreign Institutional Investors (FII): 0% Domestic Institutional Investors (DII): 0% Mutual Funds: 0% Retail & Others: 54.92% This demonstrates an outstanding distribution of ownership.

What are the PE and PB ratios of Concord Drugs Ltd?

The Price-to-Earnings (PE) ratio of Concord Drugs Ltd is 48.2048, and the Price-to-Book (PB) ratio is 0.9111, as on 01 Oct 2026.

Concord Drugs Share Price

71.32+0.32 (+0.45%)

+4.88% past 1 Year

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

1 Day

+0.45%

1 Week

-5.79%

1 Month

-10.49%

3 Month

+0.63%

6 Month

-4.64%

YTD

-13.53%

1 Year

+4.88%

5 Year

+115.47%

10 Year

Max

+209.41%

YTD

10Y

MAX

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

Price Analysis

1 Day

1 Week

1 Month

3 Months

6 Months

1 Year

Low

71.01

71.00

64.00

61.00

High

74.00

78.79

82.50

84.90

89.00

92.52

About

Concord Drugs Limited was created in 1995 to manufacture and market innovative pharmaceutical products. Concord 's three core product areas are generics branded and specialty pharmaceuticals. The Company ranks among Read more

Pharmaceuticals & Drugs

Smallcap

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats

1. Premium insight available after login

2. Sign in to view full SWOT analysis

3. Unlock strengths, weaknesses, opportunities & threats

QVT

Quality

0/100-

Valuation

0/100-

Technical

0/100-

Peer Stocks

1 week

1 month

1 year

Name

SUNPHARMA-ANSE

DIVISLAB-ANSE

TORNTPHARM-ANSE

ZYDUSLIFE-ANSE

LAURUSLABS-ANSE

CIPLA-ANSE

MANKIND-ANSE

DRREDDY-ANSE

AUROPHARMA-ANSE

LUPIN-ANSE

CONCORD-XNSE

LTP

1W Low

1W High

Market cap (₹)

1771.1-38.9 (-2.15%)

1744.95

1803.60

4,20,483Cr

9343.5+49.1 (0.53%)

9115.10

9653.50

2,49,248Cr

4627.1-134.85 (-2.83%)

4591.60

4793.55

1,77,822Cr

1119.35-25.9 (-2.26%)

1105

1167.50

1,11,242Cr

2028+39 (1.96%)

1955

2063.95

1,08,062Cr

1308.9-37.95 (-2.82%)

1292.50

1350.60

1,05,427Cr

2371.1-155.9 (-6.17%)

2340.75

2540.50

99,065Cr

1195.5-4.6 (-0.38%)

1166.75

1222.65

98,492Cr

1658.4-16.6 (-0.99%)

1633.35

1739.95

94,477Cr

1960.9-68.1 (-3.36%)

1940

2035

88,806Cr

71.32-4.38 (-5.79%)

78.79

94Cr

Concord Drugs Share Price

71.32+0.32 (+0.45%)

+4.88% past 1 Year

Financial overview

Compounded Sales Growth

10 years-

5 years-

3 years-8%

Last year1%

Compounded Profit Growth

10 years-

5 years-

3 years-40%

Last year-29%

Stock Price CAGR

10 years-

5 years16%

3 years28%

1 year4%

Return on Equity

10 years3%

5 years3%

3 years2%

Last year1%

CAGR%

Sales

Profits

Returns

ROE

10Y	5Y	3Y	TTM
-	-	-8%	1%
-	-	-40%	-29%
-	16%	28%	4%
3%	3%	2%	1%

Peer Comparison

Symbol

SUNPHARMA-A

DIVISLAB-A

TORNTPHARM-A

ZYDUSLIFE-A

LAURUSLABS-A

CIPLA-A

MANKIND-A

DRREDDY-A

AUROPHARMA-A

LUPIN-A

CONCORD-X

Price	M.Cap (₹)	PE Ratio	EPS (₹)	EV/EBITDA	Annual PAT
1,763.7	₹420483 Cr	34.76	12.07	62.82	₹11479 Cr
9,326.25	₹249248 Cr	85.21	34.04	128.41	₹2568 Cr
4,632.3	₹177822 Cr	81.53	16.72	97.06	₹2163 Cr
1,120.85	₹111242 Cr	24.65	9.42	62.53	₹5040 Cr
2,037.9	₹108062 Cr	98.83	6.8	29.25	₹889 Cr
1,307.2	₹105427 Cr	31.28	9.77	57.87	₹3879 Cr
2,368.45	₹99065 Cr	48.5	13.75	71.08	₹1913 Cr
1,196.4	₹98492 Cr	30.57	5.32	63.99	₹4196 Cr
1,690	₹94477 Cr	25.45	17.95	96.84	₹3505 Cr
1,956.65	₹88806 Cr	16.06	30.95	154.35	₹5333 Cr
71.32	₹94 Cr	45.61	0.85	2.58	₹1 Cr

Profit & Loss

Consolidated

Standalone

Quarterly

Yearly

₹

Name

Net Revenue

Total Revenue

Total Expenditure

Operating Profit

Interest Expense

PBT

Net Profit

Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
₹21 Cr	₹38 Cr	₹17 Cr	₹10 Cr	₹14 Cr	₹10 Cr	₹11 Cr	₹12 Cr	₹12 Cr	₹16 Cr	₹13 Cr	₹8 Cr	₹9 Cr	₹12 Cr	₹14 Cr	₹14 Cr	₹13 Cr	₹15 Cr
₹21 Cr	₹38 Cr	₹17 Cr	₹10 Cr	₹14 Cr	₹10 Cr	₹11 Cr	₹12 Cr	₹12 Cr	₹16 Cr	₹13 Cr	₹8 Cr	₹9 Cr	₹12 Cr	₹14 Cr	₹14 Cr	₹13 Cr	₹15 Cr
₹19 Cr	₹37 Cr	₹16 Cr	₹10 Cr	₹13 Cr	₹10 Cr	₹10 Cr	₹12 Cr	₹11 Cr	₹16 Cr	₹13 Cr	₹6 Cr	₹8 Cr	₹12 Cr	₹12 Cr	₹13 Cr	₹12 Cr	₹15 Cr
₹2 Cr	₹1 Cr	₹94 L	₹1 Cr	₹1 Cr	₹1 Cr	₹1 Cr	₹88 L	₹83 L	₹35 L	₹63 L	₹2 Cr	₹1 Cr	₹97 L	₹1 Cr	₹1 Cr	₹98 L	₹68 L
₹40 L	₹40 L	₹34 L	₹49 L	₹49 L	₹61 L	₹50 L	₹47 L	₹45 L	₹50 L	₹50 L	₹43 L	₹44 L	₹50 L	₹45 L	₹42 L	₹34 L	₹24 L
₹2 Cr	₹75 L	₹30 L	₹27 L	₹16 L	₹6 L	₹53 L	₹7 L	₹4 L	-₹55 L	-₹26 L	₹80 L	₹64 L	₹14 L	₹62 L	₹24 L	₹25 L	₹8 L
₹1 Cr	₹53 L	₹22 L	₹19 L	₹12 L	₹4 L	₹23 L	₹4 L	₹3 L	-₹34 L	-₹24 L	₹56 L	₹49 L	₹16 L	₹45 L	₹18 L	₹19 L	₹3 L

Balance Sheet

Consolidated

Standalone

₹

Name

Equity And Liabilities

Share Capital

Share Warrants & Outstandings

Total Reserves

Reserve excluding Revaluation Reserve

Shareholder's Funds

Secured Loans

Deferred Tax Assets / Liabilities

Long Term Trade Payables

Long Term Provisions

Total Non-Current Liabilities

Current Liabilities

Trade Payables

Other Current Liabilities

Short Term Borrowings

Short Term Provisions

Total Current Liabilities

Total Liabilities

Total Debt

Assets

Gross Block

Less Accumulated Depreciation

Net Block

Capital Work in Progress

Non Current Investments

Long Term Investment

Long Term Loans & Advances

Total Non-Current Assets

Current Assets Loans & Advances

Inventories

Sundry Debtors

Cash and Bank

Other Current Assets

Short Term Loans and Advances

Total Current Assets

Net Current Assets (Including Current Investments)

Total Assets

Book Value

Adjusted Book Value

Mar 2025	Mar 2024	Mar 2023	Mar 2022
—	—	—	—
₹10 Cr	₹10 Cr	₹9 Cr	₹9 Cr
₹0	₹0	₹56 L	₹0
₹24 Cr	₹24 Cr	₹22 Cr	₹20 Cr
₹24 Cr	₹24 Cr	₹22 Cr	₹20 Cr
₹34 Cr	₹34 Cr	₹32 Cr	₹28 Cr
₹1 Cr	₹65 L	₹2 Cr	₹2 Cr
₹63 L	₹47 L	₹54 L	₹66 L
₹18 L	₹34 L	₹0	₹0
₹3 Cr	₹3 Cr	₹2 Cr	₹2 Cr
₹5 Cr	₹4 Cr	₹5 Cr	₹4 Cr
—	—	—	—
₹8 Cr	₹3 Cr	₹5 Cr	₹7 Cr
₹2 Cr	₹2 Cr	₹2 Cr	₹2 Cr
₹16 Cr	₹16 Cr	₹14 Cr	₹14 Cr
₹21 L	₹32 L	₹48 L	₹67 L
₹26 Cr	₹21 Cr	₹22 Cr	₹24 Cr
₹65 Cr	₹59 Cr	₹58 Cr	₹56 Cr
₹19 Cr	₹18 Cr	₹17 Cr	₹16 Cr
—	—	—	—
₹39 Cr	₹37 Cr	₹12 Cr	₹37 Cr
₹28 Cr	₹26 Cr	₹0	₹23 Cr
₹12 Cr	₹11 Cr	₹12 Cr	₹13 Cr
₹2 Cr	₹2 Cr	₹92 L	₹55 L
₹80 L	₹84 L	₹89 L	₹0
₹80 L	₹84 L	₹89 L	₹0
₹9 Cr	₹7 Cr	₹4 L	₹3 L
₹24 Cr	₹21 Cr	₹15 Cr	₹15 Cr
—	—	—	—
₹25 Cr	₹23 Cr	₹20 Cr	₹17 Cr
₹14 Cr	₹13 Cr	₹16 Cr	₹23 Cr
₹23 L	₹18 L	₹10 L	₹7 L
₹2 L	₹6 L	₹5 L	₹27 L
₹2 Cr	₹2 Cr	₹7 Cr	₹1 Cr
₹41 Cr	₹38 Cr	₹43 Cr	₹42 Cr
₹15 Cr	₹17 Cr	₹22 Cr	₹18 Cr
₹65 Cr	₹59 Cr	₹58 Cr	₹56 Cr
₹34	₹34	₹33	₹32
₹34	₹34	₹33	₹32

Cash Flow

Consolidated

Standalone

₹

Name

Profit Before Tax

Adjustment

Changes In working Capital

Cash Flow after changes in Working Capital

Cash Flow from Operating Activities

Cash Flow from Investing Activities

Cash Flow from Financing Activitie

Net Cash Inflow / Outflow

Opening Cash & Cash Equivalents

Closing Cash & Cash Equivalent

Mar 2025	Mar 2024	Mar 2023	Mar 2022
₹69 L	₹63 L	₹1 Cr	₹2 Cr
₹3 Cr	₹3 Cr	₹3 Cr	₹3 Cr
-₹21 L	-₹3 Cr	-₹2 Cr	-₹4 Cr
₹4 Cr	₹1 Cr	₹2 Cr	₹1 Cr
₹4 Cr	₹79 L	₹2 Cr	₹77 L
-₹2 Cr	-₹1 Cr	-₹2 Cr	-₹2 Cr
-₹1 Cr	₹28 L	₹62 L	₹2 Cr
-₹2 L	₹7 L	₹2 L	₹89,000
₹15 L	₹8 L	₹6 L	₹4 L
₹12 L	₹15 L	₹8 L	₹4 L

Fundamental Ratios

Consolidated

Standalone

No results found

Concord Drugs Share Price

71.32+0.32 (+0.45%)

+4.88% past 1 Year

Shareholding summary

Promoters

45.08%

FII

DII

Others

54.92%

Promoters

FII

DII

Others

Quarterly

Yearly

Shareholding Pattern

Quarterly

Yearly

Name

Promoters

FII

DII - Others

DII - MFs

Retail & Others

Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
45.08%	54.39%	54.39%	54.39%	54.39%	54.39%
0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
54.92%	45.61%	45.61%	45.61%	45.61%	45.61%

Bulk & block deals

Name

Pradeep Kumar Jain

Ganga Devi Loya

Pradeep Kumar Jain

Ganga Devi Loya

Lakshmi Prasanna Palleti

Matalia Stock Broking Private Limited

Lakhubha Solanki

Deal Date	Action	Deal Value	Deal Price	Qty Traded	Deal Type	%Stake Traded	Exchange
04 Jul 2025	Sell	38.11 L	₹54.48	69.94 K	Bulk	0.530884	BSE
03 Jul 2025	Purchase	27.51 L	₹53.25	51.66 K	Bulk	0.392068	BSE
03 Jul 2025	Sell	79.37 L	₹53.21	1.49 L	Bulk	1.132175	BSE
03 Jul 2025	Sell	6.23 L	₹53.90	11.55 K	Bulk	0.087704	BSE
30 Jun 2025	Purchase	19.94 L	₹38.66	51.57 K	Bulk	0.391431	BSE
15 Jan 2024	Sell	23.20 L	₹44.63	51.99 K	Bulk	0.394641	BSE
29 Dec 2023	Purchase	34.66 L	₹58.36	59.40 K	Bulk	0.450839	BSE
29 Dec 2023	Sell	34.28 L	₹57.71	59.40 K	Bulk	0.450839	BSE
28 Dec 2023	Purchase	24.70 L	₹48.10	51.36 K	Bulk	0.389837	BSE
28 Dec 2023	Sell	26.43 L	₹51.46	51.36 K	Bulk	0.389837	BSE

Insider trading & SAST

Client name

S Koni Reddy

S Nagi Reddy

S Manoj Kumar Reddy

S Koni Reddy

S Manoj Kumar Reddy

S Nagi Reddy

S Koni Reddy

S Manoj Kumar Reddy

S Nagi Reddy & Pacs

Reported on	Client category	Action	%Stake traded	Holding % post deal	Deal value	Deal price	Qty traded	Deal period	Deal mode	Post transaction holding	Insider/SAST	Regulation type	Security type
02 Dec 2025	Promoter	Acquisition	3.8	45.08	0	—	5 L	20 Nov 2025	Pref. Allotment	59,39,204	SAST	29(2)	—
02 Dec 2025	Promoter	Acquisition	3.8	45.08	0	—	5 L	20 Nov 2025	Pref. Allotment	59,39,204	SAST	29(2)	—
02 Dec 2025	Promoter	Acquisition	3.8	45.08	0	—	5 L	20 Nov 2025	Pref. Allotment	59,39,304	SAST	29(2)	—
24 Nov 2025	Promoter & Director	Acquisition	4.174573	10.85	49.88 L	₹9.07	5.50 L	20 Nov 2025	Preferential Offer	16,50,543	Insider Trading	—	Warrants
24 Nov 2025	Promoter & Director	Acquisition	1.13852	13.4	54.45 L	₹36.30	1.50 L	20 Nov 2025	Allotment	17,78,125	Insider Trading	—	Equity Shares
24 Nov 2025	Promoter & Director	Acquisition	1.518027	23.2	72.60 L	₹36.30	2 L	20 Nov 2025	Allotment	30,60,536	Insider Trading	—	Equity Shares
24 Nov 2025	Promoter & Director	Acquisition	5.313093	24.7	63.49 L	₹9.07	7 L	20 Nov 2025	Preferential Offer	37,60,536	Insider Trading	—	Warrants
24 Nov 2025	Promoter & Director	Acquisition	1.13852	8.3	54.45 L	₹36.30	1.50 L	20 Nov 2025	Allotment	11,00,543	Insider Trading	—	Equity Shares
24 Nov 2025	Promoter & Director	Acquisition	4.174573	15.31	49.88 L	₹9.07	5.50 L	20 Nov 2025	Preferential Offer	23,28,125	Insider Trading	—	Warrants
31 Oct 2023	Promoter	Acquisition	3.52	55.4	0	—	3.42 L	27 Oct 2023	Pref. Allotment	55,40,649	SAST	29(2)	—

Concord Drugs Share Price

Price Analysis

Share Price Live Stats

Share Market Cap & Key Ratios Overview

About

Stock Analysis (SWOT)

QVT

Peer Stocks

Concord Drugs Share Price

Concord Drugs Share Price

Financial overview

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Peer Comparison

Profit & Loss

Balance Sheet

Cash Flow

Fundamental Ratios

Concord Drugs Share Price

Concord Drugs Share Price

Oscillators

Moving averages

Concord Drugs Share Price

Shareholding summary

Shareholding Pattern

Bulk & block deals

Insider trading & SAST

Concord Drugs Share Price

Corporate Actions

Company details

Concord Drugs Share Price

Corporate filings & documents

Announcements

Annual reports

Concalls & investor presentations

Concord Drugs Share Price

News

Concord Drugs - Quaterly Results

Concord Drugs reports Profit after tax of 51.70 Lakhs, in the March 2026 quarter

Concord Drugs reports Profit after tax of 21.50 Lakhs, in the December 2025 quarter

Concord Drugs soars on bagging orders worth Rs 14.71 crore in December

Concord Drugs bags orders worth Rs 14.71 crore in December

Concord Drugs informs about disclosure

Concord Drugs informs about disclosure

Concord Drugs informs about disclosure

Concord Drugs reports Profit after tax of 19.30 Lakhs, in the September 2025 quarter

Concord Drugs informs about compliance certificate

Concord Drugs - Quaterly Results

Concord Drugs - Quaterly Results

Concord Drugs - Quaterly Results

Concord Drugs reports Profit after tax of 11.20 Lakhs, in the June 2025 quarter

Concord Drugs reports Profit after tax of 0.80 Lakhs, in the March 2025 quarter

Concord Drugs - Quaterly Results

Concord Drugs - Quaterly Results

Concord Drugs - Quaterly Results

Concord Drugs reports Profit after tax of 22.20 Lakhs, in the December 2024 quarter

Concord Drugs - Quaterly Results

Concord Drugs Ltd Share Price Today

Concord Drugs Quick Links

Other Stocks

Calculators

Brokerage Calculator

Stock Average Calculator

MTF Calculator

Margin Calculator

Span Margin Calculator